The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.

开始日期-

申办/合作机构

Sugen, Inc.

NCT00005931 / Completed临床2期

A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma

The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).

开始日期-

申办/合作机构

Sugen, Inc.

100 项与 Sugen, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Sugen, Inc. 相关的专利（医药）

登录后查看更多信息

125

项与 Sugen, Inc. 相关的文献（医药）

2006-09-05·Proceedings of the National Academy of Sciences of the United States of America1区 · 综合性期刊

The Nck-interacting kinase phosphorylates ERM proteins for formation of lamellipodium by growth factors

1区 · 综合性期刊

Article

作者: Blackwood, Elizabeth M. ; Srivastava, Jyoti ; Wright, Jocelyn H. ; Sillman, Amy L. ; Baumgartner, Martin ; Madson, Nikki ; Barber, Diane L. ; Schilling, James W.

The mammalian Ste20-like Nck-interacting kinase (NIK) and its orthologs Misshapen in Drosophila and Mig-15 in Caenorhabditis elegans have a conserved function in regulating cell morphology, although through poorly understood mechanisms. We report two previously unrecognized actions of NIK: regulation of lamellipodium formation by growth factors and phosphorylation of the ERM proteins ezrin, radixin, and moesin. ERM proteins regulate cell morphology and plasma membrane dynamics by reversibly anchoring actin filaments to integral plasma membrane proteins. In vitro assays show that NIK interacts directly with ERM proteins, binding their N termini and phosphorylating a conserved C-terminal threonine. In cells, NIK and phosphorylated ERM proteins localize at the distal margins of lamellipodia, and NIK activity is necessary for phosphorylation of ERM proteins induced by EGF and PDGF, but not by thrombin. Lamellipodium extension in response to growth factors is inhibited in cells expressing a kinase-inactive NIK, suppressed for NIK expression with siRNA oligonucleotides, or expressing ezrin T567A that cannot be phosphorylated. These data suggest that direct phosphorylation of ERM proteins by NIK constitutes a signaling mechanism controlling growth factor-induced membrane protrusion and cell morphology.

2006-05-01·Molecular cancer therapeutics2区 · 医学

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

2区 · 医学

Article

作者: Moss, Katherine G. ; Laird, A. Douglas ; Potapova, Olga ; Mendel, Dirk B. ; Nannini, Michelle A. ; Li, Guangmin ; Cherrington, Julie M. ; Barone, Angela

Abstract:

Recent achievements in the development of multitargeted molecular inhibitors necessitate a better understanding of the contribution of activity against individual targets to their efficacy. SU11248, a small-molecule inhibitor targeting class III/V receptor tyrosine kinases, including the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors, KIT and FLT3, exhibits direct effects on cancer cells as well as antiangiogenic activity. Here, we investigated the contributions of inhibiting individual SU11248 target receptors to its overall antitumor efficacy in tumor models representing diverse signaling paradigms. Consistent with previous results, SU11248 was highly efficacious (frequently cytoreductive) in all models tested. To elucidate the specific contributions of inhibition of PDGF and VEGF receptors to the in vivo efficacy of SU11248, we employed two selective inhibitors, SU10944 (VEGF receptor inhibitor) and Gleevec (PDGF receptor inhibitor). SU10944 alone induced a tumor growth delay in all models evaluated, consistent with a primarily antiangiogenic mode of action. In contrast, Gleevec resulted in modest growth inhibition in tumor models in which the cancer cells expressed its targets (PDGFRβ and KIT), but was not efficacious against tumors not driven by these target receptor tyrosine kinases. Strikingly, in all but one tumor model evaluated, the antitumor efficacy of SU10944 combined with Gleevec was similar to that of single-agent SU11248, and was greatly superior to that of each compound alone, indicating that the antitumor potency of SU11248 in these models stems from combined inhibition of both PDGF and VEGF receptors. The one exception was a model driven by an activated mutant of FLT3, in which the activity of SU11248, which targets FLT3, was greater than that of SU10944 plus Gleevec. Moreover, SU10944 combined with Gleevec inhibited tumor neoangiogenesis to an extent comparable to that of SU11248. Thus, the potent efficacy of SU11248 in models representing diverse signaling paradigms results from simultaneous inhibition of individual target receptors expressed both in cancer cells and in the tumor neovasculature, supporting the hypothesis that multitargeted inhibitors have the cumulative antitumor efficacy of combined single-target inhibitors. [Mol Cancer Ther 2006;5(5);1280–9]

2006-03-01·Journal of the American College of Cardiology1区 · 医学

Adventitial Microvessel Formation After Coronary Stenting and the Effects of SU11218, a Tyrosine Kinase Inhibitor

1区 · 医学

Article

作者: Tony Hong ; Renu Virmani ; David W. Holdsworth ; Amit Segev ; Anthony R. Howlett ; Duncan J. Stewart ; Bradley H. Strauss ; Nafiseh Nili ; Michael J. Cole ; John G. Moffat ; Kenneth E. Lipson ; Asim N. Cheema ; Beiping Qiang ; Frank Kolodgie

OBJECTIVES:

The aim of this study was to delineate the temporal profile of adventitial microvessel (Ad-MV) formation after stenting, its relationship to arterial wall hypoxia, and the effects of a tyrosine kinase inhibitor (TKI), SU11218, on Ad-MV and in-stent intimal hyperplasia (IH).

BACKGROUND:

Adventitial microvessels have been reported after arterial injury; however, the underlying stimulus for this response and its relationship to IH is unknown.

METHODS:

Coronary stenting was performed in 40 pigs randomized to SU11218 (n = 20) or placebo (n = 20). Vessel wall hypoxia was assessed by pimonidazole adducts and hypoxia-inducible factor (HIF)-1 alpha expression. Adventitial microvessels were quantified by three-dimensional microscopic computed tomography (3D micro CT). Intimal hyperplasia was measured by intravascular ultrasound (IVUS), 3D micro CT, and morphometry. The effects of SU11218 were assessed in vitro on smooth muscle cell (SMC) and endothelial cell (EC) functions and in vivo on Ad-MV and IH.

RESULTS:

Hypoxia was evident in the vessel wall at 48 h and persisted for four weeks. Adventitial microvessels increased significantly at one week (24 +/- 7 microvessels/segment) and four weeks (23 +/- 7 microvessels/segment) compared with uninjured arteries (16 +/- 2 microvessels/segment; p < 0.001) and correlated with IH (r = 0.77, p < 0.001). The TKI SU11218 inhibited platelet-derived growth factor receptor-beta phosphorylation, EC and SMC DNA synthesis, and migration in a dose-dependent manner in vitro and significantly inhibited Ad-MV (16 +/- 5 vs. 23 +/- 7 microvessels/segment in placebo, p < 0.001) and produced approximately 80% reduction in IH (0.52 +/- 0.51 mm2 vs. 2.47 +/- 1.66 mm2 in placebo, p < 0.001) at four weeks in vivo.

CONCLUSIONS:

Arterial stenting causes arterial wall hypoxia followed by Ad-MV formation. The TKI SU11218 inhibits both Ad-MV formation and IH and represents a promising therapeutic agent to prevent in-stent restenosis.

项与 Sugen, Inc. 相关的新闻（医药）

2024-09-10

·GlobeNewswire-Health Care

Passage Bio Welcomes Tom Kassberg to Board of Directors

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission forward during this critical time for the organization," said Will Chou, M.D., president and chief executive officer of Passage Bio. "Mr. Kassberg brings a wealth of experience from his time at Ultragenyx, where he leads business development and alliance management and has directly contributed to the company's success in advancing new treatments, including a number of gene therapies in late-stage development, for rare diseases. His deep understanding of strategic planning and corporate development make him exceptionally well-equipped to guide Passage Bio as we pursue PBFT02 across several neurodegenerative indications. We're thrilled to have him join our team." Mr. Kassberg is a seasoned biotech executive with deep expertise in corporate development and strategic planning. Prior to his role at Ultragenyx, Mr. Kassberg served as Executive Vice President of Corporate Development at Proteolix, Inc, leading business development and strategic initiatives. Before that, he was Senior Vice President of Corporate Development and Commercial Operations at InterMune, Inc. Mr. Kassberg co-founded Plexxikon, where he led business and corporate development, and earlier, was Senior Director of Business Development and Corporate Licensing at SUGEN, where he played a key role during its acquisition by Pharmacia. His career began at Bristol Myers Squibb in strategic planning, managed care sales and financial analysis. "I am excited to join the Passage Bio Board of Directors and contribute to the continued growth of the company,” said Mr. Kassberg. “The remarkable progress of the PBFT02 program and opportunity to expand into additional indications highlight Passage Bio’s dedication to making a critical impact in the field of neurodegenerative diseases. I look forward to collaborating with this exceptional team to drive forward our promising treatments and make a meaningful impact on the lives of patients and their families." Mr. Kassberg earned a B.A. in economics and management from Gustavus Adolphus College and an M.B.A. from Northwestern University’s Kellogg School of Management. About Passage Bio Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com. For further information, please contact: Investors:Stuart HendersonPassage Bio267.866.0114shenderson@passagebio.com Media:Mike BeyerSam Brown Inc. Healthcare Communications312.961.2502MikeBeyer@sambrown.com

高管变更

2024-07-03

·药融圈

中科大校友&美国院士创立Biotech，融资累计1.73亿美元

▲8月15-16日 NDC2024生物医药创新者峰会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。药融云数据（www.pharnexcloud.com）监测显示：2024年2月29日，中国科大资深803应用化学校友崔景荣博士（Jean Cui）创立的新药公司BlossomHill Therapeutics，宣布完成了1亿美元的B轮融资。此轮融资由Colt Ventures领衔，Cormorant Asset Management、OrbiMed、维梧资本、Hercules BioVentures Partners、Plaisance Capital Management以及H&D Asset Management在内的新老投资者参与。Colt Ventures 合伙人 Sundeep Agrawal ，维梧资本 Timothy Stubbs 加入董事会。至此，公司累计融资金额总额达1.73亿美元（A轮融资7100万美元；种子轮200万美元）。 2024年2月6日，崔景荣博士因为在SUGEN/辉瑞以及原东家TP（Turning Point Therapeutics后被BMS以41亿美元收购）抗癌新药研发领域的杰出成就而当选美国工程院院士（NAE)，这是货真价实的头衔。曾经主导开发上市的产品有crizotinib (XALKORI®), lorlatinib (LOBRENA®)和 repotrectinib (AUGTYRO®)。 BlossomHill最早成立于2020年6月，重点开发的疾病领域为肿瘤与自身免疫。由崔景荣博士与医药老兵李一山（Y. Peter Li）博士共同创立。值得注意的是，这是一对新药伉俪。此前，崔景荣博士曾在SUGEN, Inc.担任项目负责人和团队领导；2003-2013年，她加入辉瑞，担任Associate Research Fellow，和Senior Principal Scientist。2013年，她加入Turning Point Therapeutics, Inc，担任Turning Point的首席科学官，2013年10月-2020年6月担任董事会成员。药融云数据（www.pharnexcloud.com）监测显示：新公司涉及的专利与激酶和大环策略相关，涵盖的靶点有KRAS（WO2024015262A1）、EGFR、TYK2等等。目标开发出能与阿斯利康的三代FEGFR Tagrisso竞争的候选药物；急性髓性白血病适应症的新分子；目前自身免疫候选分子也尚未公开。参考： NMPA/CDE；药融云数据，www.pharnexcloud.com； FDA/EMA/PMDA；相关公司公开披露； https://bhtherapeutics.com/； https://bhtherapeutics.com/2024/02/blossomhill-therapeutics-closes-100-million-series-b-financing/； https://www.businesswire.com/news/home/20240229403573/en；等等。本文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐 [ 重磅苏州新药峰会推荐 ] 08/15AM FDA对细胞和基因治疗 (CGT) 产品的监管 09:00-09:10 致辞 09:10-09:30 新兴医疗产品的概述 09:30-10:00 FDA对CGT产品CMC方面的监管。 10:00-10:30 FDA 对 CGT 产品非临床研究的要求 10:30-11:00 CGT 产品临床试验的注意要点 11:00-12:00 小组讨论 12:00-13:30 午餐 08/15PM FDA对核酸和基因编辑产品的监管 13:30-14:00 核酸产品的 CMC 注意要点 14:00-14:30 FDA对核酸产品的非临床要求 14:30-15:00 核酸产品的临床注意要点 15:00-15:30 FDA对溶瘤病毒产品的监管 15:30-16:00 FDA 批准首个基因编辑产品 Casgevy - 案例研究 16:00-17:00 小组讨论以上议程更新中，以会议现场为准... 门票注册通道【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

并购基因疗法细胞疗法高管变更

2024-05-15

·BioSpace

Infinimmune Appoints Dr. Neela Patel to Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)-- Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of a new independent director, Neela Patel, Ph.D., to the company's Board of Directors. Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals. “We are thrilled to welcome Neela as an independent Board member,” said Dr. Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “With over 25 years of leadership experience spanning drug discovery, development, strategic partnerships, and corporate development, she brings invaluable expertise to Infinimmune. Her proven track record of pipeline development and strategic collaborations will be invaluable as we continue to advance our programs and pursue new opportunities for growth.” “I am excited to join Infinimmune and contribute to its mission of identifying and developing truly human therapeutics to develop safer, more effective therapies for patients,” said Patel. “I look forward to contributing my expertise in deal-making and drug discovery to the long-term success of Infinimmune. The outstanding team and transformative platform technology position the company to build a remarkable pipeline.” Dr. Patel is a scientist and business development executive with more than 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation. She is currently Chief Business Officer at Bonum Therapeutics. Prior to Bonum, she was Chief Business Development Officer at Good Therapeutics, where she co-led the Roche transaction and spinout of Bonum. Previously, as Executive Director of Corporate Development at Seagen, she played an integral role in deal sourcing and execution to build the pipeline, including agreements with Pieris and FivePrime. Her sourcing and diligence at AbbVie resulted in more than 25 executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery with positions of increasing responsibility, advancing small molecules and biologics from target ID and validation through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience. Dr. Patel completed her postdoctoral training at the DNAX Research Institute after receiving her PhD in Molecular Biology from UCLA. She graduated Phi Beta Kappa from Stanford with a B.S. in Biology and a B.A. in Humanities with Honors. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.

高管变更

100 项与 Sugen, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Sugen, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

SU11655 ( c-Kit )	肿瘤更多	临床前
托西尼布 ( c-Kit )	肿瘤更多	临床前
SU11752 ( PRKDC )	肿瘤更多	临床前
SU11652 ( c-Kit )	肿瘤更多	临床前
SU-5220 ( EGFR x GRB2 x RAS )	肿瘤更多	终止